Administration of intravenous abatacept <4 weeks before knee or hip arthroplasty was not associated with an increased risk of post-operative infection compared with halting therapy >4 weeks before surgery in a study of 1,780 patients with rheumatoid arthritis (RA). No significant differences were seen in the rates of hospitalized infection (total and non-urinary), 1-year prosthetic joint infection or 30-day readmission between patients who received abatacept <4 weeks or >4 weeks before surgery; however, glucocorticoid use during the 3 months prior to surgery was associated with an increased risk of infection.